Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBIT: 2020-2025

Historic EBIT for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' EBIT rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 9.93%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EBIT stood at -$26.2 million for Q3 2025, which was down 9.52% from -$24.0 million recorded in Q2 2025.
  • Silence Therapeutics' EBIT's 5-year high stood at -$4.4 million during Q4 2024, with a 5-year trough of -$12.9 billion in Q1 2021.
  • Moreover, its 3-year median value for EBIT was -$16.5 million (2023), whereas its average is -$18.5 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 99.90% in 2022, then slumped by 409.03% in 2025.
  • Quarterly analysis of 5 years shows Silence Therapeutics' EBIT stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then fell by 28.39% to -$16.5 million in 2023, then surged by 73.63% to -$4.4 million in 2024, then increased by 12.51% to -$26.2 million in 2025.
  • Its EBIT was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.